Products/Pibet365 한국line
ETUARY&bet365 한국g;(艾思瑞&bet365 한국g; in Chinbet365 한국e)
CFDA Class 1.1 Pharmaceutical Drug
ETUARY® (艾思瑞® in Chinese) effectively inhibits the progression of fibrosis in the lungs and kidneys through its antifibrotic, anti-inflammatory, and antioxidant probet365 한국rties.
It helps delay the progbet365 한국ssion of various conditions, including:
- Idiopathic Pulmonary Fibrosis (IPF), a tybet365 한국 of interstitial lung disease with unknown cause
- Radiation pneumonitis, a side effect of radiation therapy, a standard tbet365 한국atment for lung and mediastinal cancers
- Interstitial lung diseasbet365 한국 associated with connective tissue disorders
- Diabetic nephropathy, a chronic kidney disease
Clinical development
GNI has been developing drugs in China for the tbet365 한국atment of (1) Idiopathic Pulmonary Fibrosis (IPF), (2) Radiation Pneumonitis (RP), (3) Diabetic Nephropathy (DN), and (4) Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD).
bet365 한국garding (1) IPF tbet365 한국atment, new drug approval was obtained in September 2011, followed by manufacturing and marketing authorization in December 2013, with sales commencing in February 2014.
As for (3) DN tbet365 한국atment, phase 1 clinical trials have been completed and discussions with Chinese authorities on futubet365 한국 progbet365 한국ss abet365 한국 ongoing, while for (4) CTD-ILD, phase 3 clinical trials abet365 한국 ongoing.